Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Halozyme - The Real Truth

Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO

3 Biotech Stocks Showing Promising Returns for October

3 Biotech Stocks Showing Promising Returns for October

Technological advancements and the growing investment in developing healthcare infrastructures are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Halozyme Therapeutics (HALO), BioMarin Pharmaceutical (BMRN), and United Therapeutics (UTHR). Read more.

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary

Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Antares Pharma Stock Is Soaring Today

Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027. Antares' suite of FDA-approved and partner products utilizing…

Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

inkl

Read news from The Economist, FT, and more,
with one subscription

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact

Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact

Halozyme Therapeutics Inc (NASDAQ: HALO) has

Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 r

1

Organisations

National Institutes of Health

BioMarin Pharmaceutical Inc

United Therapeutics Corporation

Tonix Pharmaceuticals

Twist Bioscience

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

375,295 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play